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Tuberous sclerosis (TSC) is a relatively common hamartoma syndrome caused by mutations in either of two genes,
TSC1 and TSC2. Here we report comprehensive mutation analysis in 224 index patients with TSC and correlate
mutation findings with clinical features. Denaturing high-performance liquid chromatography, long-range poly-
merase chain reaction (PCR), and quantitative PCR were used for mutation detection. Mutations were identified
in 186 (83%) of 224 of cases, comprising 138 small TSC2 mutations, 20 large TSC2 mutations, and 28 small
TSC1 mutations. A standardized clinical assessment instrument covering 16 TSC manifestations was used. Sporadic
patients with TSC1 mutations had, on average, milder disease in comparison with patients with TSC2 mutations,
despite being of similar age. They had a lower frequency of seizures and moderate-to-severe mental retardation,
fewer subependymal nodules and cortical tubers, less-severe kidney involvement, no retinal hamartomas, and less-
severe facial angiofibroma. Patients in whom no mutation was found also had disease that was milder, on average,
than that in patients with TSC2mutations and was somewhat distinct from patients with TSC1mutations. Although
there was overlap in the spectrum of many clinical features of patients with TSC1 versus TSC2 mutations, some
features (grade 2–4 kidney cysts or angiomyolipomas, forehead plaques, retinal hamartomas, and liver angiomy-
olipomas) were very rare or not seen at all in TSC1 patients. Thus both germline and somatic mutations appear
to be less common in TSC1 than in TSC2. The reduced severity of disease in patients without defined mutations
suggests that many of these patients are mosaic for a TSC2 mutation and/or have TSC because of mutations in
an as-yet-unidentified locus with a relatively mild clinical phenotype.
Introduction
Tuberous sclerosis (TSC [MIM 605284, MIM 191092])
is an autosomal dominant condition characterized by
seizures, mental retardation, and development of wide-
spread hamartomatous lesions (Jozwiak et al. 1994;
Kwiatkowski and Short 1994; Webb et al. 1996; Ewalt
et al. 1998; Gomez et al. 1999). TSC affects 1/6,000–
10,000 individuals (Sampson et al. 1989; Osborne et al.
1991). Two-thirds of cases are sporadic, without ante-
cedent family history, reflecting a high spontaneous mu-
tation rate. Inactivating mutations in either TSC1 or
TSC2 cause this tumor suppressor–gene syndrome (Eu-
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ropean Tuberous Sclerosis Consortium 1993; van Sleg-
tenhorst et al. 1997). TSC1 consists of a 3.4-kb coding
region with 21 coding exons, spanning 50-kb genomic
extent on 9q34, and TSC2 consists of a 5.4-kb coding
region with 41 exons and spans 40-kb genomic extent
on 16p13.
So far, 154 patients with mutations in TSC1 and 292
patients with mutations in TSC2 have been reported
(Cheadle et al. 2000; Human Genetics Online Review
Tables). Fifteen or more of these have been seen recur-
rently, but none accounts for 15% of all patients (Eu-
ropean Tuberous Sclerosis Consortium 1993; Sampson
et al. 1997; van Bakel et al. 1997; van Slegtenhorst et
al. 1997, 1999; Au et al. 1998; Beauchamp et al. 1998;
Kwiatkowska et al. 1998; Young et al. 1998; Jones et
al. 1999). Most (88%) identified mutations are small
changes—38% small deletions or insertions and 50%
nonsense, splice-site, or missense point mutations. Large
genomic deletions and rearrangements account for 12%
of identified mutations and have been reported exclu-
sively in TSC2. A number of methods have been used
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to identify mutations in these two genes: heteroduplex
analysis using conformation-sensitive gel electrophore-
sis (van Slegtenhorst et al. 1997; Kwiatkowska et al.
1998), SSCP (Au et al. 1998; Beauchamp et al. 1998;
Young et al. 1998; Jones et al. 1999; van Slegtenhorst
et al. 1999), denaturing-gradient gel electrophoresis
(Dabora et al. 1998), the protein-truncation test (van
Bakel et al. 1997; Mayer et al. 1999), pulsed-field gel
electrophoresis combined with Southern blotting (Eu-
ropean Tuberous Sclerosis Consortium 1993; Sampson
et al. 1997), and FISH (Michalet et al. 1997). The most
comprehensive analysis performed to date in a large
series of patients with TSC used a combination of SSCP
and heteroduplex analysis, as well as screening for large
deletions by several methods, and yielded mutations in
130 of 163 patients: a detection rate of 80%, which
improves to 87% if some patients without defined mu-
tations after large deletion screening are removed (Jones
et al. 1999, 2000).
In this same series, it appeared that patients with mu-
tations in TSC1 (hereafter denoted “TSC1 disease” and
distinguished from “TSC2 disease”) had less mental re-
tardation on average than patients with TSC2 disease.
To avoid bias, the analysis was restricted to sporadic
patients only, and 59 (67%) of 88 patients with sporadic
TSC2 had mental retardation, compared with 4 (32%)
of 13 patients with TSC1 disease ( , Fisher’sPp .0145
exact test; Jones et al. 1999). However, this has not
been seen uniformly (Kwiatkowska et al. 1998; Niida
et al. 1999; van Slegtenhorst et al. 1999), and no study
has examined the influence ofTSC1 disease versusTSC2
disease on the myriad other clinical features of TSC.
Here we present an analysis of 224 unselected and
sequentially ascertained patients with TSC, derived
largely from pediatric neurology practices in three sep-
arate geographic locations. We have developed a com-
bination of efficient methods to comprehensively iden-
tify mutations in TSC1 and TSC2. A clinical instrument
for recording clinical data on patients with TSC was
also developed and applied at each center. These meth-
ods have yielded both a very high detection rate of mu-
tations in TSC1 and TSC2 in these unselected patients
(83% overall) and significant new information on the
difference in phenotype between patients with TSC1
and TSC2 disease.
Subjects and Methods
Patients and Clinical Assessment
The patients with TSC that we studied were a con-
secutive, unselected series of 224 index patients derived
from four sources: 36 were obtained through patient-
derived requests, all from the United States; 105 were
derived from an academic pediatric neurology practice
in Warsaw, Poland; and 83 were derived from academic
pediatric neurology practices in the United States (65
from Cincinnati and 18 from Boston). All patients pro-
vided informed consent, and this study was approved
by institutional review boards at each institution. All
patients encountered at each institution with an initial
diagnosis of TSC were offered participation. Although
initially included in these cohorts, 14 patients were not
studied because of either a lack of an adequate DNA
sample or failure to meet formal TSC diagnostic criteria
(Roach et al. 1998). An additional three patients were
dropped after partial mutational analysis, when it was
discovered that they failed to meet diagnostic criteria.
Standardized clinical information was collected pro-
spectively on all patients and updated by additional stud-
ies and follow-up during the period of mutational anal-
ysis. This information consisted of the age and family
status of the patient and 16 different measures of both
the clinical and radiographic features of TSC (see fig. 1).
The information was collected by persons blinded to the
mutational status of the patients. General clinical fea-
tures of the patients from Warsaw, Cincinnati, and Bos-
ton were determined by clinicians experienced in the
manifestations of TSC (S.J., D.F., and E.T.). Medical re-
cords were reviewed for the patients studied through
mail solicitation. Specialized examinations or radio-
graphic studies were used to assess the extent of lesions
in the brain, kidney, liver, retina, and heart. Most man-
ifestations were graded according to a binary scale
(present or absent), but several features were graded in
severity at 3–5 levels, including mental retardation, fa-
cial angiofibromas, kidney and liver angiomyolipomas
(AMLs), kidney cysts, and lung involvement. In addi-
tion, for a subset of patients in which high-resolution
brain magnetic-resonance imaging (MRI) and/or com-
puted-tomography (CT) scans were available, the num-
ber of subependymal nodules (SENs) and cortical tubers
were counted. Most of these studies were reviewed by
a single radiologist (J.E.).
Mutational Analysis of Exons by Denaturing High-
Performance Liquid Chromatography (DHPLC)
DNA was extracted from leukocytes or from Epstein-
Barr virus–transformed lymphoblastoid cell lines by
use of standard methods. Primers were designed by
use of TSC1 and TSC2 genomic sequence information
(GenBank accession numbers AC002318, AC002096,
and AC005600) and the GCG version 8 primer program
or the WI Primer 3 program. Amplified fragments were
186–507 bp in length. A detailed description of our
method of performing DHPLC is published elsewhere,
describing its application to exons 1–20 of TSC2 (Choy
et al. 1999). For analysis of the remaining exons of these
genes, similar methods were used, and complete infor-
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Figure 1 TSC clinical features grading form
mation on amplicons and run conditions is available
(Tuberous Sclerosis [TSC] Project Web site). After com-
pletion of analysis of patient DNA samples using a single
set of run conditions for DHPLC, we modified the tem-
perature for 20 exons in which analysis by the WAVE-
MAKER 3.4 software (Transgenomic) or by the DHPLC
MELT program (N. F. Hansen and P. Oefner) suggested
that higher or lower temperatures might detect addi-
tional sequence variants. All samples remaining without
identified mutations were then analyzed under these dif-
ferent conditions. Four additional mutations were de-
tected in this manner.
PCR was performed using AmpliTaq Gold (PE Bio-
systems) in 20-ml reactions with 10–50 ng of genomic
DNA. Amplified fragments showing a DHPLC elution
shift were confirmed in a repeat analysis. Sequence var-
iation was identified by bidirectional sequencing using
an ABI 377 machine (PE Biosystems) with Big Dye ter-
minator chemistries (PE Biosystems). Sequence traces
were analyzed using the GAP4 program of the Staden
package, and sequence variation within TSC1 and TSC2
was positioned using the VARIATION WIZARD pro-
gram (Tuberous Sclerosis [TSC] Project). This program
permits inspection of genomic and cDNA sequence in-
formation for alignment and interpretation of sequence
variation. It is freely available from M.P.R. In two am-
plicons with DHPLC shifts, no sequence variation could
be detected, despite repeated sequencing analyses. In
those cases, the amplified fragments were cloned and
tested by mixing studies and DHPLC analysis, and the
variant sequence was identified by sequencing.
Missense mutations were considered to be noncon-
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servative amino acid substitutions if they had a negative
score in the BLOSUM matrix (Henikoff and Henikoff
1992). A table of polymorphisms discovered during this
study is available (Tuberous Sclerosis [TSC] Project Web
site).
Mutational Analyses for Large Deletions and Insertions
Two methods were used for identification of larger
deletions, insertions, and genomic rearrangements. First,
long-range PCR was performed (Dabora et al. 2000).
Large amplicons for long-range PCR were chosen to
provide overlapping coverage of the entire 40-kb ge-
nomic extent of TSC2 in 19 fragments of size 1.7–11.6
kb. PCR products were analyzed by electrophoresis on
0.8% agarose gels with long run times, to permit visual
identification of fragments smaller or larger than nor-
mal. Such fragments were gel purified and reamplified
with additional PCR primers, to permit isolation and
sequencing of the junction site of all apparent deletions
and insertions. Multiplex long-range PCR was also per-
formed using a single forward primer and multiple re-
verse primers (each 115 kb from the forward primer),
to enable detection of larger deletion fragments.
Second, quantitative PCR was performed for detection
of large deletions and duplications (Yau et al. 1996;
Morgan et al. 1999). 6-FAM–labeled forward primers
were used with unlabeled reverse primers for multiplex
PCR of selected TSC2 exons. Primer sequences were
identical to those used for single TSC2 exon amplifi-
cation used for DHPLC (see Tuberous Sclerosis [TSC]
Project Web site). Sets of exons of TSC2 were amplified
in multiplex PCR as follows—set 1: exons 4, 7, and 26;
set 2: exons 7, 16, and 26; and set 3: exons 25, 26, and
36. In each of these sets, TSC1 exon 17 was also am-
plified as a control. PCR conditions were identical to
those used for DHPLC analysis, except that multiple
primer pairs were present in individual PCR reactions
at concentrations from 0.25 to 0.75 mM to normalize
the amount of amplicon generated for each exon, and
only 18 cycles of PCR were performed, to ensure that
amplification was still in the exponential phase. PCR
products were analyzed by electrophoresis of 2 ml on
4.25% polyacrylamide gels on the ABI 377. Electro-
pherogram patterns were analyzed and quantitated using
GENESCAN version 3.1 software (PE Biosystems). All
samples were analyzed in duplicate, and those that in-
dicated a probable deletion were repeated for confir-
mation. Every PCR reaction set and gel run also included
at least one positive control sample with a deletion pre-
viously defined by long-range PCR and five control
samples.
To determine whether a deletion or duplication of an
exon had occurred, we calculated the relative amount
of each TSC2 exon produced in the multiplexed PCR
reaction according to the method described elsewhere
(Yau et al. 1996). For example, to calculate the dosage
quotient (DQ) of TSC2 exon 4 in an unknown sample
(U), in comparison with a control sample (C), the fol-
lowing formula was used:
DQ (U)pTSC2ex4
Area TSC2 exon 4(U)/Area TSC1 exon 17(U)
.
Area TSC2 exon 4(C)/Area TSC1 exon 17(C)
We actually used the average value of five control sam-
ples run on the same gel as the denominator in this
calculation. Control samples have DQ values in the
range of 0.80–1.25 (Yau et al. 1996). DQ mean values
!0.61 were scored as exon deletions, and mean values
11.30 were scored as exon duplications. For each de-
letion patient, the SD of 4 DQ measurements was
0.11; for each duplication patient, the SD of 4 DQ
measurements was 0.41. One patient DNA sample re-
peatedly gave intermediate values in the 0.61–0.80 in-
terval, average 0.73 ( ), which we scored as a mo-np 4
saic deletion.
Paternity and Maternity Testing
Paternity and maternity testing was performed for all
families in which TSC2 missense mutations were found
in sporadic patients and in which parental DNA samples
were available. This was performed by analysis of at
least three highly informative microsatellite markers
(D15S127, D15S131, D16S515, and D16S520), using
fluorescently labeled primers and analysis by gel elec-
trophoresis on the ABI 377 and GENESCAN version
3.1 software.
Statistical Analysis
Statistical comparisons were performed using the
STATVIEW version 5.0 package for the Macintosh.
Fisher’s exact test was used for the analysis of categorical
variables, and Student’s unpaired t test was used for the
analysis of quantitative variables.
Results
Patient Characteristics
Two hundred twenty-four patients meeting formal di-
agnostic criteria for TSC were studied. These were de-
rived by sequential ascertainment without selection and
were primarily from three academic pediatric neurology
settings (tables 1and 2). The index patients were 1–51
years old, with a median age of 10 years and an average
age of 11.5 years. Eighty-three percent of index patients
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Table 1
Patient Characteristics
CHARACTERISTIC
NO. (%) OF PATIENTS AGED
1–5 years 6–10 years 11–15 years 16–25 years 125 years
All 67 (30) 54 (24) 45 (20) 42 (19) 16 (7)
Sporadic TSC 56 (31) 44 (24) 36 (20) 35 (19) 12 (7)
Familial TSC 10 (26) 10 (26) 9 (23) 6 (16) 3 (8)
TSC1 mutation 7 (25) 8 (32) 3 (11) 7 (25) 3 (11)
TSC2 mutation 45 (28) 36 (23) 35 (22) 33 (21) 9 (6)
were sporadic cases, 8% were from families in which
there were two affected individuals, and 9% were from
families in which there were three or more affected in-
dividuals. All of the two-patient families contained an
affected parent and child; there were no families with
two affected children and unaffected parents.
Detailed clinical data were collected on each patient,
using a standardized clinical instrument that covers the
classic clinical features of TSC, including both physical
and radiographic findings (fig. 1). Several clinical fea-
tures were graded according to severity. For a subset of
patients in which high resolution brain CT and/or MRI
scans were available, the number of SENs (CT or MRI)
and/or cortical tubers (MRI) were counted. A summary
of the clinical findings in these patients is presented in
table 3. Adjusting for age, the prevalence of brain, kid-
ney, and skin involvement in this cohort is similar to
that in other series (Jozwiak et al. 1992, 1994, 1998;
Webb et al. 1996; Ewalt et al. 1998; Gomez et al. 1999),
with a slightly higher frequency of neurologic manifes-
tations, consistent with ascertainment of most patients
through neurology practices.
We compared the clinical features in sporadic patients
with the clinical features seen in index members of fa-
milial cases (table 3). The familial-case index patients
had a somewhat lower frequency of seizures than spo-
radic patients (82% vs. 93%, ) and a signifi-Pp .055
cantly lower frequency of hypomelanotic macules (82%
vs. 94%, ). However, there was no significantPp .02
difference between those two groups for all other fea-
tures. When this analysis was repeated considering only
those patients with TSC2 mutations (see below), there
were no significant differences.
Mutation Analysis
We used three complementary strategies for mutation
detection in these patients: DHPLC analysis of amplified
exons, long-range PCR amplification within the TSC2
gene, and quantitative PCR analysis of TSC2 amplicons.
These were performed in a sequential manner and were
chosen on the basis of their sensitivity and the known
mutation spectrum of TSC1 and TSC2 genes (Cheadle
et al. 2000).
When DHPLC was used, 166 small mutations were
detected in these 224 patients (table 4 and fig. 2); 138
(83%) of these mutations occurred in TSC2 and 28
(17%) in TSC1. There were 44 (27%, 12 in TSC1 and
32 in TSC2) small deletions, 14 (8%, 3 in TSC1 and 11
in TSC2) small insertions, 48 (29%, 11 in TSC1 and 37
in TSC2) nonsense mutations, 29 (17%, 2 in TSC1 and
27 in TSC2) point mutations affecting splice sites, and
31 (19%, all in TSC2) missense mutations.
Missense and in-frame–deletion mutations accounted
for 44 (32%) of 138 of all small TSC2 mutations and
were not seen in TSC1. Thirty-five missense changes and
in-frame deletions in TSC2 were confirmed as mutations
(mis-c, in-f, del-c in table 4) if either the mutation was
shown to be present in a sporadic patient with TSC and
not present in parental samples or if similar evidence
had been obtained elsewhere by others. When directly
confirmed in this way, we also confirmed, by analysis
using three microsatellite markers each with heterozy-
gosity 180%, that parental samples were authentic. In
nine cases in which parental samples were not available,
eight missense changes and one in-frame deletion were
considered to be probable mutations (mis-pr, in-f, and
del-pr in table 4) if the change in amino acid was non-
conservative. In addition, of the 23 unique missense
changes in TSC2, 21 occurred at amino acids identical
in rat and mouse Tsc2, and 20 occurred at amino acids
identical in fugu (Kim et al. 1995; Kobayashi et al. 1995;
Maheshwar et al. 1996). The other three residues that
had changed in fugu were very conservative substitu-
tions, in contrast to the missense mutations we identified.
Four unique missense mutations (mis-spl in table 4) seen
in five patients were predicted by computational analysis
(Berkeley Drosophila Genome Project, Splice Site Pre-
diction by Neural Network) to cause a change in RNA
splicing.
Seventy-nine (48%) of the 166 small mutations are
novel mutations never before reported; 130 of the 166
have not been reported by us previously. Twenty-one
mutations were seen more than once in this cohort,
from two to nine times, in a total of 59 patients. The
most frequent mutation seen here, 5238–5255del18
1746delHIKRLR, is an in-frame deletion mutation that
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Table 2
Patient Origins and Families
Characteristic No. (%) of Patients
Patient origin:
US/mail 36 (16)
Warsaw 105 (47)
Cincinnati 65 (29)
Boston 18 (8)
Family:
Sporadic 183 (83)
Small familya 17 (8)
Familyb 21 (9)
Unknown 3
a Denotes a family in which there are
only two affected members.
b Denotes a family in which three or
more individuals are affected.
was seen in nine patients (4%) in this cohort. This de-
letion occurs in the sequence context of a direct repeat
of 11 of the 18 residues lost in the deletion. Two patients
were found to have two distinct mutations within TSC2.
One patient had both a nonsense mutation and a mis-
sense mutation, and the other had both a deletion mu-
tation and a missense mutation, in each case affecting
different exons of TSC2. The missense mutations were
confirmed in one case and were probable in the other.
Seventeen large-deletion and 3 large-duplication mu-
tations were identified in TSC2, 6 by long-range PCR
and 14 by quantitative PCR (table 5). Long-range PCR
was performed using 33 different sets of amplification
primers and detected 6 deletions, ranging in size from
440 bp to 39 kb. The deletion junctions have been se-
quenced in all cases, and four of these have been reported
elsewhere (Dabora et al. 2000). The remaining 15 de-
letions/duplications were detected by quantitative PCR
(fig. 3). Because our quantitative PCR assay analyzes
only a subset of the TSC2 exons, the exact size and
location of each deletion or duplication has not been
determined. One patient was mosaic for a deletion of
exons 25, 26, and 36, since the dosage quotients (see
Subjects and Methods section) for these exons were con-
sistently between 0.61 and 0.8.
Genotype-Phenotype Comparisons
We examined the clinical manifestations of patients
with different types of mutations to see whether there
was any correlation between mutation type and specific
clinical features. A major consideration in this analysis
is the relative ages of patients in the subsets being com-
pared, since many TSC clinical features are age-depen-
dent in their expression (Jozwiak et al. 1994, 1998;
Kwiatkowski and Short 1994; Webb et al. 1996; Gomez
et al. 1999). For this reason, comparisons involving men-
tal retardation were restricted to age 6 years; those
involving facial angiofibroma were restricted to age 2
years, and those involving lymphangioleiomyomatosis
of the lung were restricted to females age 16 years.
The first major comparison was between patients with
TSC1 disease and those with TSC2 disease.
Sporadic patients with TSC1 disease had an age range,
average age, and median age that was similar to that of
sporadic patients with TSC2 disease (table 1 and top of
table 3). However, the majority of clinical features were
seen at a substantially higher frequency and/or severity
in the set of patients with sporadic TSC2 than in the set
of patients with sporadic TSC1 (table 3, 12/16 clinical
measures), with statistically significant differences in
eight clinical features. We initially excluded familial
cases from this analysis, to avoid ascertainment bias,
even though the difference between clinical features in
familial cases and sporadic cases was relatively minor,
as above. Seizures were significantly more common in
patients with sporadic TSC2 than those with TSC1
(98% vs. 86%, ); moderate to severe mentalPp .02
retardation was more frequent in patients with TSC2
(46% vs. 14%, ), and the average level (scalePp .04
0–3) of mental retardation was also higher in patients
with TSC2, compared with those with TSC1 (1.4 vs.
0.67, ). These clinical manifestations werePp .007
matched by similar differences in brain radiographic
findings. Twenty-nine (69%) of 42 patients with TSC2
had 110 tubers identified by MRI examination, com-
pared with 1 (11%) of 9 patients with TSC1 (Pp
); the average tuber count was significantly higher.002
in patients with TSC2, compared with those with TSC1
(12.9 vs. 4.4, ), and patients with TSC2 hadPp .002
more SENs than patients with TSC1 (6.7 vs. 1.7, Pp
)..0002
Renal cystic disease occurred at similar rates in pa-
tients with sporadic TSC2, compared with those with
TSC1 (25% vs. 16%, ), but patients with TSC1Pp NS
who had renal cysts were also somewhat older than pa-
tients with TSC2 who had renal cysts (26.3 vs. 13.8
years, ). There was also a higher frequency ofPp .07
grade 2–4 renal cystic disease in patients with TSC2
(19% vs. 0%, ). Renal AMLs were seen at higherPp .08
frequency and had a higher average grade in patients
with TSC2, compared with those with TSC1 (60% vs.
31%, ; mean grade 0.97 vs. 0.32, ;Pp .03 Pp .006
respectively). Several dermatologic manifestations of
TSC tended to be more severe in patients with TSC2
mutations. The mean grade of angiofibromas was higher
in patients with TSC2 than in those with TSC1 (1.5 vs.
0.9, ), despite the older average age of the pa-Pp .02
tients with TSC1 who had those lesions, and a fibrous
forehead plaque was seen more commonly in patients
with TSC2 than in those with TSC1 (40% vs. 10%,
). Although ungual fibroma were seen at similarPp .01
frequency in the two groups, the average age of patients
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Table 3
Clinical Features of the Patients, with Comparisons of Sporadic versus Familial and TSC1 Versus TSC2 Mutation Subsets
All (n p 224)
P, Sporadic (np 38)
vs. Familial (n p 183)
TSC1 Sporadic
Cases (n p 22)
TSC2 Sporadic
Cases (n p 129)a
P, Sporadic
TSC1 vs. TSC2
Age range 1–51 (11.5) NS 2–51 (13.4) 1–44 (11.2) NS
Median age (years) 10 9 10
Neurologic features:
Seizures: 202/223 (93%) NS (.055) 19/22 (86%) 127/128 (99%) .02
Age range 1–50 (11.5) 2–50 (12.3) 1–44 (11.4) NS
Mental handicap (age 6):
Mild  moderate  severe 102/155 (66%) NS 7/14 (50%) 66/90 (73%) NS
Moderate  severe 65/155 (42%) NS 2/14 (14%) 41/90 (46%) .04
Age range 6–44 (12.0) 9–24 (13.1) 6–44 (11.7) NS
Mean grade (scale 0–3) 1.25 .67 1.4 .007
Subependymal nodules: 177/193 (92%) NS 15/20 (75%) 127/136 (93%) .02
Age range 1–51 (11.6) 2–51 (13.4) 1–44 (11.6) NS (.055)
Mean SEN number 4.7 1.7 6.7 .0002
SEGA: 23/207 (11%) NS 2/21 (9%) 13/118 (12%) NS
Age range 3–44 (14.7) 9–11 (10) 4–44 (15.9)
Tubers (any): 100/113 (88%) NS 13/15 (87%) 55/60 (92%) NS
110 tubers 40/78 (51%) NS 1/9 (11%) 29/42 (69%) .002
Age range 1–50 (11.4) 2–50 (11.7) 1–44 (11) NS
Mean tuber number 10.2 4.4 12.9 .002
Renal features:
Kidney cysts:
Grades 1–4 52/207 (25%) NS 3/19 (16%) 30/122 (25%) NS
Grades 2–4 29/207 (14%) 0/19 (0%) 19/122 (16%) NS (.08)
Grade 4 6/207 (3%) 0/19 (0%) 5/122 (4%) NS
Age range 1–50 (13.6) 9–50 (26.3) 1–44 (13.8) NS (.07)
Mean grade (scale 0–4) .46 .16 .52 NS (.14)
Kidney AMLs: 113/207 (55%) NS 6/19 (31%) 72/121 (60%) .03
Age range 1.5–44 (13.2) 9–21 (11.8) 1.5–44 (13.8) NS
Mean grade (scale 0–3) .83 .32 .97 .006
Skin features:
Hypomelanotic macules: 202/219 (92%) .02 20/21 (95%) 124/128 (97%) NS
Age range 1–51 (11.2)
Facial angiofibromas (age 2): 155/208 (75%) NS 13/22 (59%) 95/121 (78%) NS
Age range 2–51 (14.3) 4–51 (18.5) 2–44 (13.6) NS (.09)
Mean grade (scale 0–3) 1.4 .9 1.5 .02
Shagreen patch: 100/210 (48%) NS 7/20 (35%) 68/130 (52%) NS
Age range 2–51 (13.1) 4–51 (18.9) 2–42 (12.7) NS (.06)
Ungual fibroma: 39/215 (18%) NS 5/20 (25%) 26/128 (20%) NS
Age range 4–51 (21) 6–51 (29.2) 4–42 (18.7) NS (.07)
Forehead plaque: 74/217 (34%) NS 2/20 (10%) 51/128 (40%) .01
Age range 2–42 (13.3) 6–20 (13) 2–42 (13.5) NS
Other features:
Liver AMLs: 12/195 (6%) NS 0/15 9/117 (8%) NS
Age range 3–38 (16.7) 10–38 (17.4)
Retinal hamartomas: 46/192 (24%) NS 0/16 32/117 (27%) .01
Age range 1–44 (12.8) 1.5–44 (13.2)
Cardiac rhabdomyoma: 100/195 (51%) NS 8/17 (47%) 58/117 (50%) NS
Age range 1–33 (9.6) 3–20 (7.6) 1–23 (8.5) NS
LAM (females, age 16): 5/48 (11%) NS 0/5 3/17 (18%) NS
Age range 18–37 (27.4) 18–37 (25.3)
NOTE.—Age range (average age [in years]) considers all patients with positive findings. SEGA p subependymal giant cell astrocytoma.
a Mosaic case with large TSC2 deletion not included in this analysis.
with TSC1 was significantly higher than that for patients
with TSC2 with this finding (29.2 vs. 18.7 years, Pp
). Retinal hamartomas were also seen with increased.07
frequency in the patients with TSC2, compared with
those with TSC1 (27% vs. 0%, ). There was aPp .01
suggestion of an increased frequency of lymphangioleio-
myomatosis (LAM) of the lung in patients with TSC2,
compared with those with TSC1, but this did not achieve
Table 4
Small Mutations in TSC1 and TSC2 Identified by DHPLC
Patient Gene/Exona Mutationb
Mutation
Typec
Family
Typed
De
novoe Reportedf First Author (year)
LR115 TSC1E07 868-869delTT del S u, o van Slegtenhorst (1997)
BG1601 TSC1E08 954CrT 245RrX non F u, o
BG401 TSC1E08 954CrT 245RrX non S u, o
BHM3901 TSC1E08 954CrT 245RrX non S u, o
BHM4201 TSC1E09 970insT ins S n
BHM1001 TSC1E09 1055–1056delTC del S n
LR821 TSC1E09 1122–11341del14 del S u Kwiatkowska (1998)
LR721 TSC1E10 1209–1210delCT del S o van Slegtenhorst (1997)
BHM7001 TSC1E15 1746CrT 509RrX non smF u, o
ONK431 TSC1E15 1746CrT 509RrX non S u, o van Slegtenhorst (1997)
BG101 TSC1E15 1918delC del S n
ONK381 TSC1E15 1929–1930delAG del S u, o van Slegtenhorst (1997)
ONK661 TSC1E15 1950GrT 577ErX non F u
ONK421 TSC1E15 2109–2112delAAAG del S u, o van Slegtenhorst (1997)
ONK741 TSC1E15 2109–2112delAAAG del smF u, o Kwiatkowska (1998)
LR911 TSC1E15 2124–2125delAC del S u, o van Slegtenhorst (1997)
LR251 TSC1E15 2181CrT 654QrX non S u Kwiatkowska (1998)
BG1001 TSC1E17 2295CrT 692RrX non S o
BHM3301 TSC1E17 2355–2359delCATCG del S n
ONK711 TSC1E17 2394–2397delAAAG del S u Kwiatkowska (1998)
ONK641 TSC1E18 2448CrT 743QrX non U u, o van Slegtenhorst (1997)
BHM4601 TSC1E18 2520CrT 767QrX non S n
ONK781 TSC1E18 2577CrT 786RrX non S u, o van Slegtenhorst (1997)
BHM5101 TSC1E19 2722insA ins S n
LR100 TSC1E20 2729–2108delAAAC del S u, o Kwiatkowska (1998)
BG801 TSC1E20 2790insG ins F n
BHM2501 TSC1I04 432–1GrA spl S o
BHM7101 TSC1I04 432–1GrA spl S o
ONK121 TSC2E03 268CrT 90QrX non S u Choy (1999)
ONK1071 TSC2E04 357delC del S u Choy (1999)
ONK841 TSC2E04 415delA del S u Choy (1999)
LR811 TSC2E05 569insA ins S u Choy (1999)
ONK221 TSC2E06 618CrA 206CrX non S n
ONK451 TSC2E07 731GrA 244CrY mis-c S Yes n
LR841 TSC2E07 759CrA 253CrX non S n
ONK861 TSC2E07 774GrC 258KrN mis-spl-c S Yes u Choy (1999)
ONK311 TSC2E08 782GrC 261RrP mis-pr S u Choy (1999)
ONK831 TSC2E08 826–827delAT del S o
BHM602 TSC2E09 871insC ins S u Choy (1999)
BHM3601 TSC2E09 911GrA 304WrX non S n
BHM1103 TSC2E09 972CrG 324YrX non S u Choy (1999)
ONK251 TSC2E09 972CrG 324YrX non F u
LR951 TSC2E10 1082TrC 361LrP mis-c S Yes u Choy (1999)
BHM5301 TSC2E10 1093–1095delATC 365delI in-f del-c S o
ONK341 TSC2E10 1096GrT 366ErX non S n
BHM1401 TSC2E11 1219TrG 407YrD mis-pr S u, o Choy (1999)
ONK1031 TSC2E11 1255CrT 419PrS mis-spl-c S Yes n
Z61 TSC2E12 1336CrT 446QrX non S u Choy (1999)
BHM4701 TSC2E13 1372CrT 458RrX non S o
BHM5701 TSC2E13 1372CrT 458RrX non S o
ONK351 TSC2E13 1372CrT 458RrX non S o
ONK881 TSC2E13 1372CrT 458RrX non S o
ONK1001 TSC2E13 1407delG del S n
BHM4401 TSC2E14 1472CrA 491SrX non S n
ONK1091 TSC2E14 1513CrT 505RrX non S o
BHM1601 TSC2E16 1783CrT 595QrX non S n
LR601 TSC2E16 1831CrT 611RrW mis-c S u, o Choy (1999)
ONK571 TSC2E16 1831CrT 611RrW mis-c S u, o Choy (1999)
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BHM3201 TSC2E16 1832GrA 611RrQ mis-c U Yes o
BHM4301 TSC2E16 1832GrA 611RrQ mis-c S Yes o
KS31 TSC2E18 1965insT ins S n Choy (1999)
BHM802 TSC2E18 2081–2083delTGC 694delL in-f del-c S Yes u Choy (1999)
ONK1151 TSC2E19 2108GrA 703WrX non S o
LR941 TSC2E19 2158–2171insGTCCCTGCGCTATA ins S u Choy (1999)
ONK551 TSC2E19 2182delT del S n
BHM2301 TSC2E19 2210–2214insGCTCT ins S n
LR901 TSC2E20 2225CrG 742SrX non S u Choy (1999)
ONK111 TSC2E20 2240–2241delTG del S n
KS41 TSC2E20 2251CrT 751RrX non S u, o Choy (1999)
ONK531 TSC2E20 2251CrT 751RrX non S u, o Choy (1999)
BHM7301 TSC2E20 2328CrA 776YrX non* S n
ONK731 TSC2E21 2440GrA 814ErK mis-c F n
ONK501 TSC2E23 2687GrA 896WrX non S n
ONK921 TSC2E23 2714GrA 905RrQ mis-pr S n
ONK291 TSC2E24 2785GrT 929ErX non S n
ONK161 TSC2E26 3094CrT 1032RrX non F n
ONK761 TSC2E26 3094CrT 1032RrX non smF n
LR921 TSC2E26 3098insA ins S n
ONK191 TSC2E26 3098insA ins S n
ONK23 TSC2E26 3098insA ins S n
ONK391 TSC2E26 3099CrA 1033YrX non S n
ONK981 TSC2E27 3178TrC 1060WrR mis-c S Yes n
ONK1081 TSC2E27 3212CrG 1071TrR mis-c S Yes n
BHM1901 TSC2E27 3214delA del F n
ONK701 TSC2E27 3220–3221delGG; 3221 insC del F n
BHM3401 TSC2E29 3412CrT 1138RrX non S o
BHM401 TSC2E29 3412CrT 1138RrX non S o
BHM5801 TSC2E29 3412CrT 1138RrX non S o
LR831 TSC2E29 3412CrT 1138RrX non S o
ONK51 TSC2E29 3574delC del S n
ONK181 TSC2E30 3685CrT 1229QrX non S n
Z51 TSC2E30 3685CrT 1229QrX non S n
BHM6701 TSC2E30 3750CrG 1250YrX non S n
BHM6501 TSC2E32 3984delG del smF n
BG1701 TSC2E33 4096GrT 1366ErX non S n
ONK401 TSC2E33 4255delC del S n
ONK41 TSC2E33 4375CrT 1459RrX non S o
Z81 TSC2E33 4375CrT 1459RrX non S o
BG1402 TSC2E33 4422–4423delAG del F o
ONK371 TSC2E33 4427–4430insTAGA ins S n
ONK961 TSC2E33 4439TrA 1480LrX non S n
BG1901 TSC2E34 4544–4547delACAA del S o
ONK271 TSC2E35 4598–4626ins29bp ins smF n
ONK1051 TSC2E35 4606CrT 1536QrX non S n
ONK1181 TSC2E35 4645TrA 1549YrN mis-pr S n
BHM1801 TSC2E35 4655–4657delAAG 1552delE in-f del-c S Yes n
ONK1121 TSC2E36 4672GrA 1558ErK mis-c S Yes n
ONK11 TSC2E36 4790TrC 1597LrP mis-c S Yes n
ONK891 TSC2E36 4823–4825delACT 1608delY in-f del-pr S n
BHM503 TSC2E36 4825–4831delTGCTGGC del S n
BHM3801 TSC2E37 4854delC del S n
ONK751 TSC2E37 4927ArC 1643NrH mis-pr S n
ONK561 TSC2E37 4934–4935delTT del smF o
BHM3001 TSC2E37 4943TrC 1648IrT mis-pr S n
ONK91 TSC2E37 4952ArG 1651NrS mis-spl-c F o
ONK581 TSC2E37 4989insG ins S n
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BHM103 TSC2E38 5024CrT 1675PrL mis-c F o
BHM2601 TSC2E38 5024CrT 1675PrL mis-c S o
LR851 TSC2E38 5024CrT 1675PrL mis-c S Yes o
ONK61 TSC2E38 5024CrT 1675PrL mis-c S o
ONK71 TSC2E38 5024CrT 1675PrL mis-c S o
ONK991 TSC2E38 5024CrT 1675PrL mis-c S o
BHM6101 TSC2E38 5051–506816del34 del* S o
ONK681 TSC2E39 5108TrG 1703VrG mis-pr S n
ONK871 TSC2E39 5126CrG 1709PrR mis-c S Yes n
BHM6301 TSC2E39 5126CrT 1709PrL mis-spl-c S Yes o
ONK591 TSC2E39 5126CrT 1709PrL mis-spl-c S Yes o
ONK81 TSC2E40 5167TrC 1723SrP mis-pr S n
BG301 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c smF o
LR61 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S o
LR801 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S o
LR871 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S Yes o
ONK1101 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S Yes o
ONK1141 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S Yes o
ONK231 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S o
ONK261 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S o
ONK281 TSC2E40 5238–5255del18 1746delHIKRLR in-f del-c S o
BHM302 TSC2E40 5252–525919del27 del F n
ONK522 TSC2E40 5252–525919del27 del smF n
ONK362 TSC2I01 1381GrA spl F o
ONK901 TSC2I01 1385GrA spl S Yes u Choy (1999)
BG1501 TSC2I03 3362TrG spl S n
Z21 TSC2I03 337–1GrT spl S u Choy (1999)
BG1802 TSC2I05 600–2ArG spl S n
BHM1301 TSC2I07 7742TrA spl S u Choy (1999)
ONK211 TSC2I08 849–1GrA spl S u Choy (1999)
BG1301 TSC2I09 976–15GrA spl S o
ONK171 TSC2I09 976–15GrA spl smF o
ONK1061 TSC2I11 1258–2ArC spl S n
ONK631 TSC2I11 1258–3CrG spl S n
BG701 TSC2I13 1444–1GrA spl S o
BHM2001 TSC2I18 2098–1GrA spl F n
ONK821 TSC2I19 2221–2ArC spl S n
BHM2701 TSC2I22 26391GrC spl S n
LR931 TSC2I23 2743–2ArC spl S n
BG601 TSC2I23 2743–2ArG spl U n
ONK144 TSC2I23 2743–1insGCCAG spl F n
ONK601 TSC2I26 313111–313128del18 spl-pr smF n
ONK851 TSC2I29 36101GrA spl S n
BG201 TSC2I32 40051GrT spl S n
BHM902 TSC2I35 4663–1GrA spl S n
ONK131 TSC2I35 4663–1GrA spl S n
LR961 TSC2I38 5069–1GrA spl S n
ONK811 TSC2I39 51601GrA spl smF n
ONK331 TSC2I39 5161–1GrA spl S n
ONK514 TSC2I39 5161–1GrA spl smF n
a Mutations are listed in the order TSC1 exon mutations, TSC1 intron mutations, TSC2 exon mutations, TSC2 intron mutations.
b Nomenclature is per Antonarakis (1998). TSC1 numbering uses A of initiator ATG as 222; TSC2 numbering uses A of initiator
ATG as 1.
c del p deletion; non p nonsense; ins p insertion; spl p splice site; mis p missense; in-fr del p in-frame deletion; mis-spl p
missense and probable splice site change; c p confirmed; pr p probable. *, patient with two mutations.
d S p sporadic; smF p family with two affected members; F p family with more than two affected members.
e “Yes” means shown by parental DNA analysis to be de novo.
f o p others; u p us (previous reports); n p novel.
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Table 5
Mutations in TSC2 Identified by Long-Range and Quantitative
PCR
Patient TSC2 Deletion/Duplication Detection Method
BHM1501 4.5-kb deletion, introns 2–5 Long PCRa
BHM1701 39-kb deletion, introns 1–40 Long PCRa
ONK 10-1 34-kb deletion, introns 1–33 Long PCRa
ONK 101-1 1.4-kb deletion, exons 37–39 Long PCRa
BG501 440-bp deletion, intron
39–3′ UTR
Long PCR
BHM 4001 465-bp deletion, introns
9–10
Long PCR
BHM5401 Duplication, exon 25 Quantitative PCR
BHM5501 Duplication exons 7, 16,
and 25
Quantitative PCR
BHM5901 Duplication exons 16 and
25
Quantitative PCR
JR 1-1 Deletion, exons 7, 16, 25,
26, and 36
Quantitative PCR
LR 89-1 Deletion, exons 4, 7, 16, 25,
26, and 36
Quantitative PCR
ONK 15-1 Deletion, exons 25, 26, and
36
Quantitative PCR
ONK 24-1 Deletion, exon 36 Quantitative PCR
ONK 46-1 Deletion, exons 4, 7, 16, 25,
26, and 36
Quantitative PCR
ONK 116-1 Deletion, exons 4 and 7 Quantitative PCR
BHM2901 Deletion, exons 16, 25, and
26
Quantitative PCR
BHM4901 Deletion, exons 4, 7, 16, 25,
26, and 36
Quantitative PCR
BHM6801 Deletion, exon 36 Quantitative PCR
ONK 95-1 Deletion, exon 7 Quantitative PCR
BG1201 Mosaic deletion, exons 25,
26, and 36
Quantitative PCR
a Reported elsewhere (Dabora et al. 2000).
Figure 2 Map of the sites of small mutations in TSC1 and TSC2. Proportional drawings (boxes) of all of the exons of TSC1 and TSC2
are shown. Intron regions are not drawn to scale and are expanded only when a mutation is present. Mutation symbols are xp nonsense; 
p splice site;  p deletion;  p insertion;  p missense; and  p in-frame deletion. A line separates mutations occurring at nearby but
not identical nucleotide positions.
statistical significance because of small numbers of fe-
male patients of age 116 years (3/17 patients with TSC2
had LAM vs. 0/5 patients with TSC1).
When this analysis between TSC1 and TSC2 muta-
tions was repeated using both sporadic patients and fa-
milial index patients, similar results were obtained with
generally similar levels of confidence (table 6). The dif-
ferences in the frequency of grade 2–4 kidney cysts (17%
vs. 0%, ) and mean grade of kidney cysts (0.55Pp .03
vs. 0.125, ) become significant in this larger pop-Pp .05
ulation (table 6).
We also compared the clinical features of the 38 pa-
tients in whom no mutations could be identified in sep-
arate analyses with patients with TSC1, patients with
TSC2, and TSC1 and TSC2 patients combined (table 6).
We expected that this group was a composite of patients
whose mutations may not have been detected for several
different reasons. The “no mutation identified” (NMI)
group had clinical features that were generally less severe
than those in patients with TSC2 mutations and were
generally similar to clinical features of patients with
TSC1 mutations. The NMI group had a lower incidence
of seizures, mental retardation, cortical tubers, SENs,
hypomelanotic macules, facial angiofibromas, Shagreen
patch, and forehead plaque in comparison with patients
with TSC2 mutations. They also had a lower average
SEN count, tuber count, and grade of facial angiofibro-
mas. Most of these comparisons were also significant
when made between the NMI group and patients with
both TSC1 and TSC2 combined. This may be partly
because TSC2 cases significantly outnumberTSC1 cases.
When NMI patients were compared with patients with
TSC1, many clinical features were seen at similar fre-
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Figure 3 Analysis of deletions and duplication events by quantitative PCR. Representative electropherograms (left) and dosage quotient
values (right) for 3 DNA samples analyzed by quantitative PCR: control sample (top); ONK102: 34-kb deletion in TSC2 identified by long-
range PCR (middle); ONK151: deletion of TSC2 exons 25, 26, and 36 identified using quantitative PCR (bottom).
quencies (table 6). However, hypomelanotic macules
(74% in NMI vs. 96% in TSC1, ) were seenPp .03
significantly less frequently in NMI patients, compared
with patients with TSC1, whereas renal AMLs had
greater severity in NMI patients, compared with patients
with TSC1 (average level 0.66 vs. 0.29, ).Pp .05
A comparison of the clinical features of patients with
different types of TSC2 mutations was also performed,
to see whether there was any clinical correlation among
those subsets. We divided the TSC2 mutations into two
subsets for this analysis: first, chain-terminating small
mutations (insertion, deletion, nonsense, and splice-site
mutations) and large genomic deletions and second,
non–chain-terminating mutations (missense and in-
frame deletion mutations). This analysis was performed
in two different ways, once with patients with TSC2
missense/splice mutations in the first subset and then
with those patients in the second subset. In both com-
parisons, the only significant difference in clinical fea-
tures was for Shagreen patch, which was seen less often
in the missense/in-frame deletion group (38% vs. 59%,
). We suspect that this single difference repre-Pp .04
sents random chance. This provides further evidence that
TSC2 missense mutations are pathogenic and inactivat-
ing similar to other TSC2 mutations.
Discussion
We have studied the largest series of patients with TSC
yet reported and have identified mutations in 186 (83%)
of 224 cases. Twenty-eight (12%) index patients were
found to have mutations in TSC1, 138 (62%) were
found to have small mutations in TSC2, 20 (9%) were
found to have large genomic deletions in TSC2, and 38
(17%) had no mutation identified. The overall mutation
detection rate increases to 190 (88%) of 217 if we in-
clude two unconfirmed missense mutations and two
samples suspected of being mosaic cases with largeTSC2
deletions, as well as correcting the denominator to ex-
clude seven samples in which there was an inadequate
DNA supply to complete the entire analysis. The great
majority of these mutations, 148 (78%), have not been
reported elsewhere. The cumulative mutation detection
rate and distribution of mutations described here are
similar to those reported in a British cohort of 150 pa-
tients with TSC by Sampson and coworkers over the
past several years (Jones et al. 1997, 1999, 2000; Ma-
heshwar et al. 1997). The major difference seen in com-
parison of these two series is that the British cohort has
a somewhat higher frequency of genomic disruptions of
TSC2 (15% vs. 9% in this study, ). This is pos-Pp NS
sibly due to ascertainment and/or selection bias, since
there was a higher frequency of patients with TSC in
the British cohort who have polycystic kidney disease
(6% vs. 3% in this series).
We have developed two relatively novel yet techni-
cally simple strategies for detection of large genomic
rearrangements within TSC2: long-range PCR (Dabora
et al. 2000) and quantitative PCR (Yau et al. 1996).
Long-range PCR can be performed in any current mo-
lecular laboratory, requiring only a PCR machine and
agarose gel electrophoresis. Because a complete assay
of the TSC2 gene by this method requires multiple PCR
reactions, we perform this analysis only on patient sam-
ples in which no small mutation in TSC1 or TSC2 has
been detected by DHPLC. Quantitative PCR analysis is
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Table 6
Clinical Features of Patients with NMI and Comparison with Patients Who Have TSC1 and TSC2 Mutations
NMI (all)
(n p 38)
TSC1 (all)
(n p 28)
TSC2 (all)
(n p 158) P, T1 vs. T2 P, T1 vs. NMI P, T2 vs. NMI
Age range (years) (average age) 1–33 (9.8) 2–51 (14.9) 1–44 (11.3) NS NS NS
Neurologic features:
Seizures 25/37 (68%) 24/28 (86%) 153/158 (97%) .03 NS (.15) !.0001
Mental handicap (age 6
years):
Mild  moderate  severe 12/22 (54%) 10/20 (50%) 80/113 (71%) NS (.08) NS NS (.14)
Moderate  severe 9/22 (41%) 4/19 (21%) 52/113 (46%) .05 NS NS
Mean MR gr (scale 0–3) 1.1 .79 1.49 .02 NS NS
SENs: 26/34 (76%) 20/25 (80%) 131/134 (98%) .003 NS .0001
Mean SEN number 2.9 2.0 6.3 .0005 NS .0008
SEGA 2/37 (5%) 4/26 (15%) 17/145 (12%) NS NS NS
Tubers (any): 19/24 (79%) 15/18 (83%) 66/71 (93%) NS NS NS (.12)
110 tubers 6/20 (30%) 1/11 (9%) 34/47 (72%) .0002 NS .002
Mean tuber number 6.9 4.3 12.9 .0004 NS .002
Renal features:
Kidney cysts:
Grades 1–4 6/34 (18%) 3/24 (12.5%) 43/149 (29%) NS NS NS
Grades 2–4 4/34 (12%) 0/24 (0%) 25/149 (17%) .03 NS NS
Grade 4 0/34 (0%) 0/24 (0%) 6/149 (4%) NS NS NS
Mean grade .32 .125 .55 .05 NS NS
Kidney AMLs: 16/35 (46%) 7/24 (29%) 89/148 (60%) .007 NS NS
Mean grade .66 .29 .96 .001 .05 NS
Skin features:
Hypomelanotic macules 26/35 (74%) 26/27 (96%) 150/157 (95%) NS .03 .0004
Facial angiofibromas (age 2
years): 21/36 (58%) 18/28 (64%) 116/155 (75%) NS NS NS (.06)
Mean grade 1.2 1.0 1.5 .01 NS NS (.06)
Shagreen patch 9/35 (26%) 9/25 (36%) 82/153 (54%) NS NS .004
Ungual fibroma 3/35 (9%) 5/25 (20%) 31/155 (20%) NS NS NS
Forehead plaque 8/35 (23%) 3/25 (12%) 64/155 (42%) .006 NS .05
Other features:
Liver AMLs 1/31 (3%) 0/20 (0%) 11/144 (8%) NS NS NS
Retinal hamartomas 5/28 (18%) 0/20 (0%) 41/144 (28%) .004 NS (.07) NS
Cardiac rhabdomyoma 19/34 (56%) 9/21 (43%) 72/140 (51%) NS NS NS
LAM (females, age 16 years) 0/7 (0%) 0/6 (0%) 5/36 (14%) NS NS NS
NOTE.—Abbreviations are as in table 3.
also a relatively simple assay, requiring only fluores-
cently labeled primers, careful PCR technique, and a
sequencing machine with fluorescent detection capabil-
ity, such as the ABI 377 used here. The combination of
the two assays should provide detection of all deletion
mutations of size 1400 bp within the TSC2 gene. A
significant fraction of partial gene duplications and
moderate size insertions are also detected by quantita-
tive PCR and/or long-range PCR. Chromosomal trans-
locations involving TSC2 are not detected by these
methods, but these appear to be extremely rare (Eu-
ropean Tuberous Sclerosis Consortium 1993; Sampson
et al. 1997; Eussen et al. 1999; van Slegtenhorst et al.
1999).
In this analysis, we have found mutations in TSC1
in only 12% of all index patients, with very similar
detection rates in sporadic (12%) and familial (13%)
cases. The observation that TSC1 mutations account
for only a small proportion (10%–20%) of all patients
with TSC has now been made in several series studied
in multiple laboratories (Kwiatkowska et al. 1998;
Young et al. 1998; Jones et al. 1999; Niida et al. 1999;
van Slegtenhorst et al. 1999). However, our observa-
tions of families contrasts somewhat with observations
made of limited numbers of extended multigeneration
families with TSC in which linkage and mutational stud-
ies indicate there is an approximately equal frequency
of TSC1 and TSC2 mutations (Young et al. 1998; Jones
et al. 1999; Niida et al. 1999; van Slegtenhorst et al.
1999). The predominance of TSC2 mutations in the
families studied here appears to be primarily due to their
small size, since nearly half of these families consist of
just two affected individuals, and there are only six
families that extend to three or four (three families each)
generations. However, even among these extended fam-
ilies, five of six had mutations in TSC2. We conclude
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that the estimated frequency of TSC1 versus TSC2 mu-
tations in familial cases, based on previous linkage stud-
ies, may have been biased because of the small numbers
of families studied. Our data suggest that TSC2 mu-
tations are substantially more frequent in both familial
and sporadic cases than TSC1 mutations.
The greatly lower frequency of de novo mutations in
TSC1 versus TSC2 (a ratio of 1:6 in this cohort) can
be explained somewhat by examination of the genomic
structure and types of mutations that occur in these
genes. Deletion, insertion, and nonsense mutations oc-
cur at lower frequency in TSC1, compared with TSC2
(∼1:3 ratio), which is partially explained by the smaller
size of the coding region (about two-thirds) and fewer
number of exons (about one-half) in TSC1, compared
with TSC2 (fig. 2). However, splice-site and missense
mutations and genomic rearrangements are all very rare
or not seen in TSC1, in contrast to TSC2. It is the
deficiency of these latter mutation types that pushes
down the frequency of de novo mutations in TSC1 to
such a low level in comparison with TSC2. The differing
spectrum and frequency of TSC1, compared withTSC2,
mutations may be due to intrinsic differences in the
regional genomic structure of the two genes. The lack
of clearly pathogenic missense mutations in TSC1 sug-
gests the possibility that such a mutation either has no
effect or causes a different clinical phenotype, possibly
through a dominant negative effect (Cheadle et al.
2000).
The detailed analysis of clinical phenotype and its
relationship to mutation type performed here permits a
delineation of the distinctions in clinical features asso-
ciated with TSC1 versus TSC2 disease. TSC1 disease is
less severe than TSC2, by a significant margin, in mul-
tiple clinical measures that relate to brain, kidney, der-
matologic, and retinal involvement by TSC. The obser-
vations have value in the clinical setting in which genetic
counseling is offered to patients with known mutations
in either TSC1 or TSC2. It is clear, however, that there
is a wide degree of variation in clinical phenotype for
each of TSC1 and TSC2 mutations, so that a precise
prediction of the severity of clinical features cannot be
made in either case. This clinical variability is nicely
demonstrated by the nine independent patients in this
series with the TSC2 in-frame deletion mutation 5238–
5255del18 1746delHIKRLR. The age range for eight
of these patients was 7–28 years and all had seizures,
but mental retardation ranged from none to severe, fa-
cial angiofibromas ranged from none to extensive (grade
3), and renal AMLs ranged from minimal to extensive
(grades 1–3). Thus, there is extensive clinical variability
even for identical mutations.
However, it is possible to derive some clinical guide-
lines in the assessment of patients with TSC. First, pa-
tients that are either sporadic cases or from small fam-
ilies are more likely to be due to TSC2 than TSC1
mutation (odds ratio 6:1). Second, as the severity of the
disease and number of clinical features increases, so
does the chance that the patient bears a TSC2 mutation.
One way to consider this is to group all patients with
any of the following clinical features: forehead fibrous
plaque, liver AMLs, retinal hamartomas, or significant
renal involvement (grade 2 cysts or AMLs). This
group represents the majority of patients with TSC in
this series (124 [55%]). In this group, there were 3 (2%)
TSC1 mutations, 104 (84%) TSC2 mutations, and 17
(14%) without a mutation identified. Thus, any of these
clinical features strongly predicts that the patient has a
TSC2 mutation. Conversely, in the group of patients
without any of these features, TSC1 mutations are more
common (25%).
There are at least two hypotheses to explain why
TSC1 disease is less severe than TSC2 disease. First it
is possible that second-hit events (following the Knud-
son two-hit model) occur less often in TSC1 than in
TSC2. Second, it is possible that complete loss of ha-
martin, the TSC1 gene product, has different effects in
cells, compared with the loss of tuberin, the TSC2 gene
product.
The two hit model for hamartoma development in
TSC postulates that second somatic mutations occur in
the cells that give rise to TSC hamartomas (Green et al.
1994; Henske et al. 1996). This model has been well-
proven by loss of heterozygosity analysis for the renal
AMLs and cardiac rhabdomyomas of TSC, with more
provisional evidence for hamartomas involving the
brain and skin (Henske et al. 1996, 1997). A reduced
level of somatic mutation in TSC1 (second-hit events),
compared with TSC2, is implied by the reduced number
of both cortical tubers (4.4 in TSC1 vs. 12.9 in TSC2,
) and SENs (1.7 in TSC1 vs. 6.7 in TSC2,Pp .002
) in patients withTSC1, compared with thosePp .0002
with TSC2. This apparent difference in somatic muta-
tion rates between TSC1 and TSC2 is concordant with
the difference in germline mutation rates in the two
genes. However, it is possible that tuber and SEN count-
ing by MRI/CT scan only detects lesions above a certain
size, so this may not provide an accurate count of sec-
ond-hit events.
In addition, the extreme qualitative difference in kid-
ney disease in patients with TSC1 versus TSC2 may be
more consistent with the second hypothesis. No signif-
icant renal involvement was seen in any index patient
with a TSC1 mutation in this series; all had either no
or minimal (grade 1) renal cysts and AML. In contrast,
significant renal involvement (grade 2 renal cysts or
AMLs) was seen in 27% of all the patients in this series,
and mutations were identified in 53 (87%) of these 61
patients, all with TSC2. This distinction is rather strik-
ing and may fit better with a differential role of the gene
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products tuberin and hamartin in renal cell growth
control.
Similar to reports elsewhere, we found that all six pa-
tients with polycystic kidney disease had a large deletion
involving the 3′ end of the TSC2 gene and likely involving
the adjacent PKD1 gene (Sampson et al. 1997). One of
these patients was mosaic for this deletion.
Although it was not the primary intent of this study,
we also examined the correlation between clinical fea-
tures among this large patient set. Among all patients,
55 (73%) of 75 without mental retardation had sei-
zures, whereas 138 (99%) of 139 with mental retar-
dation had seizures ( ), consistent with studiesP ! .0001
elsewhere that indicate that patients with TSC without
seizures do not develop mental retardation at an ap-
preciable rate (Gomez et al. 1999). In contrast, we found
a relatively poor correlation between tuber count and
mental retardation. Mean tuber counts were 7.5 for
patients without mental retardation, 14.7 for mild, 9.7
for moderate, and 12.1 for patients with severe mental
retardation. There was a correlation between any degree
of mental retardation (tuber count 12.5) versus those
without mental retardation (7.5, ). This find-Pp .0035
ing is similar to reports elsewhere in which tuber count
has correlated to a modest degree with mental retar-
dation (Goodman et al. 1997). However, a rather strik-
ing correlation was seen between the extent of renal
AMLs and mental retardation. In index patients of age
6 years, 75 (76%) of 99 with kidney AMLs had some
degree of mental retardation, whereas only 19 (44%)
of 43 without such lesions had any degree of mental
retardation ( ). In addition, the mean gradePp .0004
of mental retardation in patients with AMLs (1.61) was
significantly higher than in those without (0.84, Pp
). Similar results were obtained when only patients.0004
with TSC2 were considered. This correlation between
renal angiomyoplipomas and mental retardation in TSC
is unexplained, although it has been noted elsewhere
(O’Callaghan et al. 2000). A direct causative relation-
ship seems biologically implausible, although it could
be viewed as simply a correlation between severity of
disease in two distinct organs.
DHPLC has proved to be an efficient tool for mu-
tation detection in TSC. It is ideally suited for genetic
disorders like TSC, in which mutations are scattered
over multiple exons, in that amplicons may be scanned
at high sensitivity and efficiency by the DHPLC tech-
nique, followed by directed sequencing. The most fre-
quent mutation in this series was seen in only 9 (4%)
of all patients, and most other recurrent mutations were
seen in only two patients. In addition, 79 of the 166
small mutations reported here in TSC1 and TSC2 have
not been previously identified by any group, indicating
that the spectrum of mutations in these two genes con-
tinues to expand. Therefore, mutation detection ap-
proaches directed at identification of specific mutations
cannot be comprehensive in this disorder.
At the conclusion of this mutational screening, we
were left with a set of 38 (17%) patients in whom no
mutation was identified, the NMI set. There are multiple
potential factors that could contribute to the lack of
identification of a definite mutation in these patients.
First, there were two patients in this set in whom mis-
sense changes in TSC2 were identified that could not
be classified as mutations because they were only mod-
erately nonconservative and parental samples were not
available. Second, there were two cases in which mo-
saicism for a large deletion in TSC2 was suspected but
results were inconclusive. Third, there were seven pa-
tients whose DNA samples were depleted before a com-
plete analysis was performed. Fourth, it is likely that
inactivating mutations remote from coding exons and
their splice boundaries occur at some rate in TSC1 and
TSC2, and these and certain other classes of mutation
will go undetected or unconfirmed as mutations by
methods that analyze DNA only. Fifth, it is possible
that there are additional causative loci that account for
a small fraction of TSC cases. Finally, we and others
have reported elsewhere that some patients with rela-
tively low level mosaicism for a TSC1 orTSC2mutation
may present with diagnostic features of TSC (Sampson
et al. 1997; Kwiatkowska et al. 1999; Verhoef et al.
1999). Some of these mutations may be difficult to de-
tect by any conventional method, particularly mosaic
single-base substitution mutations. It was of consider-
able interest to note that the NMI patients as a set had
clinical features that were significantly milder than those
of patients with TSC2 mutations and were somewhat
different from those with TSC1 mutations (table 6).
Because the numbers of these patients is relatively small,
the comparisons are of only modest statistical signifi-
cance. In addition, the NMI patient set is likely to be
a mixed grouping of patients from several of the cate-
gories listed above. Nonetheless, the observations in-
dicate that the NMI set of patients has a distinct set of
clinical features, which, in our view, suggests the hy-
pothesis that mosaicism for a mutation in TSC2 and/
or additional, as-yet-unidentified TSC loci account for
a significant fraction of these patients. Additional study
will be required to explore this hypothesis.
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